Polyphron raises $20M seed for human tissue models

What's the deal? PolyphronDealroom has a profile for this one. Try Dealroom → has raised a $20 million seed round to develop human tissue models for drug development, chief executive officer Matthew Osman told Axios exclusively.

What's the endgame? The company is building lab-grown tissue that mimics human biology. The goal is to give researchers a more reliable way to test whether a drug candidate will actually work in people.

Why it matters: AI can flag promising drug candidates, but researchers still need to confirm those predictions hold up in human biology. Polyphron's tissue models aim to close that gap.

The signal: As AI accelerates the hunt for new drugs, the bottleneck shifts to testing. Tools that validate predictions against real human tissue are becoming the next frontier in drug development.

Image credit: Generated with Gemini